27 September 2020 ARBP's future pipeline comprises differentiated and margin-accretive products in Oncology, Depot Injections, Inhalers, Biosimilars, Vaccines, Topicals, and Patches. Overall it has 6MDIs, 2 Dry Powder Inhalers (DPIs), 14 Biosimilars, 26 Topicals, 8 Transdermals, 3 Depot Injections and 2 Vaccines under development. We expect ARBP to deliver 10% sales CAGR in the US over FY20-22E. While there has been COVID-led slowdown in the EU business, ARBP remains on track to expand its product offerings, adding newer markets and increasing its penetration in existing markets. We expect ARBP to deliver 6% sales CAGR in the EU business over FY20-22E. ARBP has completed the corrective and preventive action (CAPA) at Units 1, 9, and 11/Aurolife and is awaiting feedback from the USFDA on desktop reviews. ARBP should complete the CAPA at Unit 7 soon. Aurobindo Pharma We expect ARBP to deliver 15% earnings CAGR over FY20-22E, led by new launches /increased market share in key markets of the US/EU and lower financial leverage.

Automobiles: Channel check takeaways Dismal demand climate for MHCVs. CRS: Demand trends improving. IT Services: Stellar outsourcing show- a positive readthrough for Indian IT

Suven Pharma has turned ex-bonus from September 25, 2020 pursuant to the board approval granted for the issue of bonus shares in its meeting held on September 16, 2020. The record date for the same has been fixed as September 28, 2020. The board has recommended the issue of bonus shares in proportion of one bonus share (face value of | 1 each) for every equity share held (i.e. 1:1). Consequently, the share price has changed to | 369/share from | 738/share. Accordingly, our target price has also been revised to | 385/share from | 770/share earlier. After the recent run up, the...

24 September 2020 its entry into the Refrigerator product category with the launch of 25 new models of Direct Cool, Frost Free, and Side by Side refrigerators. Going ahead, the company aims to launch 25 additional refrigerator models and a new range of dishwashers by Diwali 2020. Assuming INR10k as the price of the base model (190-liter Direct Cool refrigerator) implies a 1213% discount on a like-to-like basis v/s products offered by key brands such as LG, Samsung, and Whirlpool. The new products launched would be available across pan-India Lloyd brand stores, offline dealers, and Lloyd online e-stores. Top 3 players in the Refrigerator category LG, Samsung, and Whirlpool occupy ~80% market share. Videocons exit has resulted in market share gains for the Top 3 players, with Whirlpool being the biggest beneficiary owing to an attractive pricing point).

Key takeaways from our interaction with the management of Cera Sanitaryware (CRS).

FY23E and, 4) gVascepa could be a near-term opportunity after receiving favorable outcome from the court with expected EPS contribution of Rs4.5/1.60/0.50 in FY21/22/23E. We incorporate benefits from new launches and roll forward our base year of valuation to FY23E (from FY22E) though maintained our assigned PE 24x, given its sustainability of improved earnings visibility led by new host of launches. Our new TP is Rs5,648 (earlier Rs4,326) with gRevlimid benefit contributing Rs262/share (assigning 1x(PE) to discounted cash flow of gRevlimid benefit over FY23E-26E). We also change...

Going ahead, traction in international market, new products like oil free compressors (AB series) would aid growth while a revival is expected in the India business, which continues to face challenges across verticals. However, its strategy on cost reduction, focus on cash business would help deal with working capital, debt and liquidity situation. We expect revenue, EBITDA growth of 7.1%, 30.1% CAGR, respectively, in FY20-22E. We revise...

Seminal year for industry provides interesting insights However, amid all the gloom, the engineering and production prowess of the industry (along with its value chain) shone brightly as it successfully completed the world's fastest switchover to Euro 6 equivalent emission norms i.e. BS-VI as per schedule. Much of the post festive period was focused on the transition, with the entire ecosystem estimated to have spent ~| 70,000 crore towards the technological leap. Covid-19 crisis struck India in the run up to April 2020, just as the changeover...

Seminal year for industry provides interesting insights However, amid all the gloom, the engineering and production prowess of the industry (along with its value chain) shone brightly as it successfully completed the world's fastest switchover to Euro 6 equivalent emission norms i.e. BS-VI as per schedule. Much of the post festive period was focused on the transition, with the entire ecosystem estimated to have spent ~| 70,000 crore towards the technological leap. Covid-19 crisis struck India in the run up to April 2020, just as the changeover...

To acquire Australia-based IT firm DWS Limited, expand presence in ANZ region HCL Technologies has announced its intent to acquire Australia-based IT, business and management consulting firm DWS Limited. DWS - listed on the Australian Securities Exchange (ASX) - employed 772 people as of June-end, has offices in Melbourne, Sydney, Adelaide, Brisbane and Canberra and provides a range of IT services including Digital Transformation, Application Development & Support, Program & Project Management and Consulting, mainly in Australia and New Zealand. The acquisition will be done by a process of Scheme of Arrangement to be approved by courts in Australia. It will be subject to the approvals of...

A single bench of the Honble High Court at Calcutta vide its order dated 18th September, 2020 in a probate proceeding to which the Company is not a party has restrained Mr. Harsh V. Lodha, Non-Executive Director and Chairman of the Company from holding any office in the Company.

HCL Tech has announced its intent to acquire DWS Limited (DWS) for Australian $158.2 million (~| 849.2 crore) valuing the company at 0.94x EV/Sales (based on FY20 Sales) and ~21x FY20 EPS. The acquisition is subject to regulatory approvals and is expected completion timeline is by December 2020. The acquisition will add ~1% to company's top line in FY22E and will also help the company in expanding it's presence in Australia and New Zealand. The company will also be able to cross sell and up sell to existing clients of DWS. Although DWS's PAT margins (~4.4%) are lower...

We increase our target price to Rs5,054 to factor gRevlimid launch in FY23 and maintain our ADD rating. Key catalysts are launch of gVascepa, approval for gCopaxone and gNuvaring. Meaningful addition: Dr. Reddys settles patent litigation with Celgene (Bristol Myers Squibb) in the US for gRevlimid (USD7.6bn). The drug is indicated for multiple myeloma (cancer). As per the settlement terms, Dr. Reddys is licensed to sell volume-limited quantity after Mar 2022 and without volume-restriction after Jan 31, 2026 subject to product approval from the US FDA. While the details pertaining to launch date and market share are not disclosed, the opportunity can add an NPV of Rs384/share to our target price in a base case scenario (assuming 5-20% market share, 30-45% price erosion between FY23-26).

Scarcely helped by the pandemic, Supreme Industries reported most of the least alluring outcomes in recent past for its plastic goods volumes tumbled but by a little charming 19.4% to 91451 mt compared to 113428 mt in the year ago period. Consumer products and industrial products bore much of the brunt for they published volume decline of 70.5% and 54% respectively. Hardly weakish demand for agri-pipes, particularly rural, Tier III and Tier IV cities - boosted by GOI robust investment in infrastructure largely helped circumvent no unabysmal stress in demand...

Company reported poor Q1FY21 due to subdued economic activity in the global as well as domestic market. Explosives sales volume declined by 24.0% YoY to 70,287 MT (vs 92,531 MT in Q1FY20) while realization declined by 7.0% YoY to INR 34,238/MT (vs INR 36,969/MT). Exports and overseas revenue contribution in Q1FY21 rose to 42.2% of revenue (vs ~31.5% in Q1FY20) and saw a growth of 6.0% YoY (+19.2% QoQ). Housing and Infra declined by 49.3% YoY (-34.1% QoQ, 22% of revenue), revenue from Coal India declined 10.4% YoY (-7.5% QoQ, 20% of revenue), Institutional revenue declined ~32.2% YoY (-30.7% QoQ, 10% of revenue), defense revenue declined 7.1% YoY (-11.4% QoQ, 5% of...

Saffola franchise and cost savings to support earnings growth We recently interacted with Mr. Pawan Agarwal, CFO, Marico Ltd. (MRCO) in order to get an update on the overall operating environment and demand trends being witnessed on ground. After witnessing YoY volume growth in May-June'20, company's domestic business has seen growth in July'20 and August'20 as well. It has been primarily led by the Saffola franchise (Edible Oils and Foods), partially by coconut oil and new launches made in the health & hygiene space. On the international front, Bangladesh has managed to remain on a firm footing. Copra...

NII fell 2.9% YoY to | 563 crore on account of muted credit growth and weak margins. NIMs were down ~29 bps YoY to 2.96% on account of contraction in yields led by higher lending to social housing segment. Muted topline was offset by lower opex, which led operating profit to come in at | 518 crore. GNPA, NNPA came in at 4.33%, 0.57%, respectively, with absolute GNPA at | 3383 crore. The company said two assets in Chhattisgarh and Rajasthan (that got upgraded in Q2FY21) slipped into NPA. Exposure to Rajasthan, Chhattisgarh was at | 91 crore, | 347 crore wherein provision was at | 31...

1) sluggish scale up of operations due to localized lockdowns and 2) low consumer confidence due to rising incidence of Covid-19 cases SJET reported better than expected 1Q21 unit revenues with operating RASK...

PVR's Ind-AS adjusted EBITDA loss of Rs1,159mn was better than our estimates of Rs1,344mn as rigorous cost cutting initiatives resulted in average fixed opex burn of ~Rs320mn per month in 1QFY21 against a guidance of Rs400-450mn given at the start of the lockdown. Further, management guided for a lower burn rate of Rs220-250mn per month in 2QFY21. With reopening timelines being highly uncertain and rising instances of producers opting for the OTT route, we expect FY21E to be highly unpredictable and a complete wash out. However, we expect normalcy...

We revised our volume estimate and factor 13%YoY growth for H2FY21 and 20% growth from H1 to H2 owing to significant farm mechanization and higher government participation. Escorts Ltd (EL) is the third largest Agricultural tractor manufacturer in India. It has strong presence in the north and west market, with an overall market share of 11.6% as on FY20. Tractor demand was robust across the country. Price realisation was very good as farmer's cash flow has been very strong....